Literature DB >> 9671308

Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse.

M Vooijs1, M van der Valk, H te Riele, A Berns.   

Abstract

The yeast-derived Flp-frt site-specific DNA recombination system was used to achieve pituitary-specific inactivation of the retinoblastoma (Rb) tumor suppressor gene. Whereas mice carrying only frt sites in both alleles of Rb remain tumor free, tumorigenesis ensues when the Flp recombinase is expressed. The rate of tumorigenesis in these mice depends both on the expression level of the Flp recombinase and on the presence of frt sites in one or both Rb alleles. This permitted a more accurate definition of the consecutive steps in pituitary tumorigenesis. Our study illustrates the potential of this approach for studying sporadic cancer in a defined mouse model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671308     DOI: 10.1038/sj.onc.1202169

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Efficient gene activation in cultured mammalian cells mediated by FLP recombinase-expressing recombinant adenovirus.

Authors:  M Nakano; K Odaka; M Ishimura; S Kondo; N Tachikawa; J Chiba; Y Kanegae; I Saito
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

2.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions.

Authors:  J H Dannenberg; A van Rossum; L Schuijff; H te Riele
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

3.  Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development.

Authors:  Kerry L Ferguson; Jacqueline L Vanderluit; Jean M Hébert; W C McIntosh; Emma Tibbo; Jason G MacLaurin; David S Park; Valerie A Wallace; Marc Vooijs; Susan K McConnell; Ruth S Slack
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

4.  Rb/E2F regulates expression of neogenin during neuronal migration.

Authors:  Matthew G Andrusiak; Kelly A McClellan; Delphie Dugal-Tessier; Lisa M Julian; Sonia P Rodrigues; David S Park; Timothy E Kennedy; Ruth S Slack
Journal:  Mol Cell Biol       Date:  2010-11-08       Impact factor: 4.272

Review 5.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 6.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

7.  Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycle-independent functions.

Authors:  Kelly A McClellan; Vladimir A Ruzhynsky; David N Douda; Jacqueline L Vanderluit; Kerry L Ferguson; Danian Chen; Rod Bremner; David S Park; Gustavo Leone; Ruth S Slack
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

8.  Retinoblastoma protein plays multiple essential roles in the terminal differentiation of Sertoli cells.

Authors:  Roopa L Nalam; Claudia Andreu-Vieyra; Robert E Braun; Haruhiko Akiyama; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2009-10-09

9.  Overlapping roles of pocket proteins in the myocardium are unmasked by germ line deletion of p130 plus heart-specific deletion of Rb.

Authors:  W R MacLellan; A Garcia; H Oh; P Frenkel; M C Jordan; K P Roos; M D Schneider
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.

Authors:  Hongbo Wang; Frederick Bauzon; Peng Ji; Xiaoliang Xu; Daqian Sun; Joseph Locker; Rani S Sellers; Keiko Nakayama; Keiich I Nakayama; David Cobrinik; Liang Zhu
Journal:  Nat Genet       Date:  2009-12-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.